zopapogene imadenovec†) for the treatment of adult patients with recurrent respiratory papillomatosis (RRP). The submission is in the initial 60 day review period, during which time the FDA will ...

Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment Lekha Gupta Mon, Dec 30, 2024, 12:31 PM 2 min read ...